1. Market Research
  2. > Healthcare
  3. > Medical Device
  4. > In Vitro Diagnostics Market Trends
  5. > 2016 US In Vitro Diagnostics Market: Strategic Implications of Emerging Reimbursement, Technological and Market Trends

- How will the future reimbursement changes affect individual market segments?

- Will the industry consolidate, decentralize, or undergo-bimodal transformation?

- What will be the impact on purchasing influences, marketing strategies, joint ventu

Table Of Contents

2016 US In Vitro Diagnostics Market: Strategic Implications of Emerging Reimbursement, Technological and Market Trends
I. INTRODUCTION
II. EXECUTIVE SUMMARY
A. BUSINESS-AS-USUAL SCENARIO
B. ECONOMIC AUSTERITY SCENARIO
C.TECHNOLOGICAL BREAKTHROUGHS SCENARIO
III. CONCLUSIONS AND RECOMMENDATIONS
IV.THE SCENARIOS
A. BUSINESS-AS-USUAL SCENARIO
1. Business Environment
a. Health Care Expenditures
b. Cost-Consciousness
c. Reimbursement
d. Industry Consolidation
e. Managed Care
PPOs
HMOs
f. Hospitals
g. Admissions
h. Length of Stay
i. Industry Diversification
j. Physician Demographics
k. Aging Population
Chronic Illnesses
Disease Incidence
Susceptibility to Iatrogenesis
Multiple Illness Cases
l. Laboratory Regulations
m. The FDA Reform
2. Outlook for the In Vitro Diagnostics Market
a. Government Regulations
b. Centralized Testing
Hospitals
Commercial Laboratories
Blood Banks
Public Health Laboratories
c. Decentralized Testing
Personal Testing
Physician Offices/Group Practices
Ancillary Hospital Locations
- ERs
- ORs
- ICUs/CCUs
Cancer Clinics
Ambulatory Care Centers
Surgery Centers
Nursing Homes
Birth Centers
3. Strategic Implications
a. Testing Patterns
Test Utilization
Pre-Admission Testing
Inpatient Testing
Outpatient Testing
4. Market Segments
a. Chemistry and Immunoassay
Introduction
Future Situation
b. Microbiology and Serology
Introduction
Future Situation
c. Hematology and Flow Cytometry
Introduction
Future Situation
d. Histology and Cytology
Introduction
Future Situation
e. Coagulation
Introduction
Future Situation
f. Urinalysis
Introduction
Future Situation
g. Blood Banking
Introduction
Future Situation
5.Technologies
a. Genomics
Introduction
Future Situation
b. Proteomics
Introduction
Future Situation
c. DNA Probes
Introduction
Future Situation
d. Biochips/Microarrays
Introduction
Future Situation
e. Monoclonal Antibodies
Introduction
Future Situation
f. Solid Phase Chemistry
Introduction
Future Situation
g. Biosensors
Introduction
Future Situation
h. Automation and Robotics
Introduction
Future Situation
i. Computer-Aided Diagnosis
Introduction
Future Situation
6.The New Marketplace
a. Purchasing Influences
b. Marketing Strategies
c. Joint Ventures, Mergers and Licensing
d. Import-Export
e. Potential Market Entrants
f. Who May Not Survive?
B. ECONOMIC AUSTERITY SCENARIO
1. Business Environment
a. Socio-Political Climate
Cost-Consciousness
Government Actions
Three-Tier System
Health Rationing
Voucher System
Health IRA
b. Hospital Closures
c. Hospital Utilization
d. Hospital Reorganization
e. Physician Regulations
f. Wellness Programs
g. Corporate Responses
h. Academic Research
2. Outlook for the In Vitro Diagnostics Market
a. Test Utilization
Ordering Practices
Documentation
Recertification
b.Technology Regulations
c. New Laboratory Ventures
d. Computers
e. Industrial Medicine
f. Insurance Companies
g. Test Volume and Market Size
3. Strategic Implications
a. Testing Patterns
Pre-Admission Testing
Inpatient Testing
Outpatient Testing
b. Market Segments
Chemistry and Immunoassay
Microbiology and Serology
Hematology and Flow Cytometry
Histology and Cytology
Coagulation
Urinalysis
Blood Banking
c.Technologies
Genomics
Proteomics
DNA Probes
Biochips/Microarrays
Monoclonal Antibodies and Immunoassays
Automation and Robotics
Solid Phase Chemistry
Biosensors
Computer-Aided Diagnosis
d.The New Marketplace
Purchasing Influences
Marketing Strategies
Joint Ventures, Mergers and Licensing
Import-Export
Potential Market Entrants
Who May Not Survive?
C.TECHNOLOGICAL BREAKTHROUGHS SCENARIO
1. Business Environment
a. Political/Regulatory Climate
b.-and-Funding
c. Industry-Government Relationship
d. Industry-University Ventures
e.Technological Environment
f. Testing Decentralization
g. Health Care Expenditures
h. Physician Population
i. Hospital Indicators
2. Outlook for the In Vitro Diagnostics Market
a. Overview
b. Genomics
c. Proteomics
d. DNA and RNA Probes
e. Biochips/Microarrays
f. Monoclonal Antibodies
g. Immunoassays
h. Information Technology
i. Laboratory Automation and Robotics
j. Solid Phase Chemistry
k. Biosensors
l. Holography
m. Pharmaceuticals
3. Strategic Implications
a.Testing Patterns
Pre-Admission Testing
Inpatient Testing
Outpatient Testing
Test Volume and Market Size
b. Market Segments
Chemistry and Immunoassay
Microbiology and Serology
Hematology and Flow Cytometry
Histology and Cytology
Coagulation
Urinalysis
Blood Banking
c.The New Marketplace
Purchasing Influences
Marketing Strategies
Joint Ventures, Mergers and Licensing
Import-Export
Potential Market Entrants
Who May Not Survive?
V.APPENDICES: METHODOLOGY
A.The Delphi
B. Cross-Impact Analysis
C. Substitution Modeling
Table of Contents
Executive Summary Table I: Business-As-Usual
Scenario, Growth Areas in Clinical Laboratory
Testing
Executive Summary Table II: Economic Austerity
Scenario, Growth Areas in Clinical Laboratory
Testing
Executive Summary Table III: Technological
Breakthroughs Scenario, Growth Areas in
Clinical Laboratory Testing
Executive Summary Table IV: Market Size by Location
Executive Summary Table V: Market Size by Laboratory
Discipline
Table-1: Business-As-Usual Scenario, Health
Care Costs by Expenditure Type
Table-2: Business-As-Usual Scenario, HMO and PPO
Enrollment
Table-3: Business-As-Usual Scenario, Selected
Hospital Statistics
Table-4: Business-As-Usual Scenario,Total Population
and Physician Demographics
Table-5: Business-As-Usual Scenario,Test Volume
by Location
Table-6: Business-As-Usual Scenario,Test Distribution
by Location
Table-7: Business-As-Usual Scenario, Market Size
by Location
Table-8: Business-As-Usual Scenario,Typical
Pre-Admission Tests
Table-9: Business-As-Usual Scenario,Test Volume
by Laboratory Discipline
Table-10: Business-As-Usual Scenario, Market Size
By Laboratory Discipline
Table-11: Economic Austerity Scenario, Selected
Hospital Statistics
Table-12: Economic Austerity Scenario,
HMO and PPO Enrollment
Table-13: Economic Austerity Scenario,Total Population
and Physician Demographics
Table-14: Economic Austerity Scenario, Major
Categories of Overutilized Tests
Table-15: Economic Austerity Scenario,
Test Volume by Location
Table-16: Economic Austerity Scenario,Test
Distribution by Location
Table-17: Economic Austerity Scenario,
Market Size by Location
Table-18: Economic Austerity Scenario,Timing
Requirements for Selected Laboratory Tests
Table-19: Economic Austerity Scenario,Test Volume
by Laboratory Discipline
Table-20: Economic Austerity Scenario, Market Size
by Laboratory Discipline
Table-21: Technological Breakthroughs Scenario, HMO
and PPO Enrollment
Table-22: Technological Breakthroughs Scenario,Total
Population and Physician Demographics
Table-23: Technological Breakthroughs Scenario,
Selected Hospital Statistics
Table-24: Technological Breakthroughs Scenario,
Test Volume by Location
Table-25: Technological Breakthroughs Scenario,
Test Distribution by Location
Table-26: Technological Breakthroughs Scenario,
Market Size by Location
Table-27: Technological Breakthroughs Scenario,
Test Volume by Laboratory Discipline
Table-28: Technological Breakthroughs Scenario,
Market Size by Laboratory Discipline

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
2016 Microbiology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Molecular Diagnostic, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, and Immunodiagnostic Tests

2016 Microbiology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Molecular Diagnostic, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, and Immunodiagnostic Tests

  • $ 47500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,000 pages and 550 tables, and provides granular data and analysis not available from any other published source. The survey is designed ...

2016 Hematology and Flow Cytometry Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test, Technology Trends, Opportunities for Suppliers

2016 Hematology and Flow Cytometry Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test, Technology Trends, Opportunities for Suppliers

  • $ 33500
  • Industry report
  • October 2016
  • by Venture Planning Group

This 33-country survey from VPGMarketResearch.com contains over 900 pages, 380 tables and provides granular data and analysis not available elsewhere. The survey is designed to help current suppliers and ...

2016 Europe Microbiology Analyzers and Reagents in 28 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Molecular Diagnostic, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, and Immunodiagnosti

2016 Europe Microbiology Analyzers and Reagents in 28 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Molecular Diagnostic, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, and Immunodiagnosti

  • $ 30000
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 28-country survey from VPGMarketResearch.com contains over 820 pages and 418 tables, and provides granular data and analysis not available from any other published source. The survey is designed ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.